General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Peering Into Cassava Sciences's Recent Short Interest- Benzinga | news.google.com • |
Cassava Sciences (NASDAQ:SAVA) Given New $131.00 Price Target at HC Wainwright | news.google.com • |
Cassava Sciences (NASDAQ:SAVA) Shares Down 6% | news.google.com • |
Cassava Sciences (NASDAQ:SAVA) Trading Up 9.8% | news.google.com • |
Noteworthy Tuesday Option Activity: EWCZ, SAVA, DHR | news.google.com • |
Insider Stock Buying Reaches US$831.4k On Cassava Sciences | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-10 | 2024-03 | -0.51 | -1.41 | -0.9 | -176.47% |
2024-02-28 | 2023-12 | -0.4 | -0.5 | -0.1 | -25.00% |
2023-11-07 | 2023-09 | -0.9 | -0.61 | 0.29 | 32.22% |
2023-08-03 | 2023-06 | -0.58 | -0.63 | -0.05 | -8.62% |
2023-05-01 | 2023-03 | -0.56 | -0.58 | -0.02 | -3.57% |
2023-02-28 | 2022-12 | -0.58 | -0.47 | 0.11 | 18.97% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-08 | HC Wainwright & Co. | Upgrade | Buy | |
2023-03-05 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-23 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2018-10-02 | ARMISTICE CAPITAL L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2023-05-23 | BARBIER REMI | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
2024-04-22 | BARRY RICHARD J | Director | 0.00 | Conversion of Exercise of derivative security |
2022-10-02 | FRIEDMANN NADAV | Officer and Director | 80.05K | Conversion of Exercise of derivative security |
2023-04-30 | GUSSIN ROBERT Z | Director | 10.62K | Conversion of Exercise of derivative security |
2024-04-17 | KUPIEC JAMES WILLIAM | Officer | 4.00K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 2.75M | 67.35M | 6.54% |
2023-06-29 | Vanguard Group Inc | 2.25M | 55.16M | 5.36% |
2023-06-29 | State Street Corporation | 952.09K | 23.35M | 2.27% |
2023-06-29 | Geode Capital Management, LLC | 803.31K | 19.70M | 1.91% |
2023-06-29 | Gallacher Capital Management LLC | 583.29K | 14.30M | 1.39% |
2023-06-29 | Northern Trust Corporation | 370.64K | 9.09M | 0.88% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.23M | 30.21M | 2.94% |
2023-08-30 | iShares Russell 2000 ETF | 908.42K | 19.05M | 2.16% |
2023-06-29 | Vanguard Extended Market Index Fund | 542.35K | 13.30M | 1.29% |
2023-07-30 | Fidelity Small Cap Index Fund | 353.09K | 7.76M | 0.84% |
2023-08-30 | iShares Russell 2000 Growth ETF | 333.17K | 6.99M | 0.79% |
2023-05-30 | Fidelity Extended Market Index Fund | 202.34K | 4.60M | 0.48% |
Dividend | Date |
---|---|
0.75 | 2012-12-13 |
2 | 2010-12-13 |
Split | Date |
---|---|
1 : 7 | 2017-05-10 |
Current position
You’re all fired...
Is earnings b4 or after the bell?
Winter is Coming
Fucking stock!!!
Glad my options are behind earnings (Aug 21)
So nothing??
Anything yet?
SAVA - Let's try this again? Presentation July 15 about SavaDx - Alzheimer's
DD
We have another Alzheimer's play here. Biogen (BIIB) submitted an Alzheimer's therapy to FDA for review on July 8 and its shares jumped 6%, but that's a higher-priced stock ($276) with a 162M float, compared to SAVA at 22M. Today INMB was up 120% on their Alzheimer's trial results.
Back in May, the stock dropped from around $8 to $2.5 because of bad results from a drug study (https://www.streetinsider.com/dr/news.php?id=16890142). Now they're back with a blood-based diagnostic to detect Alzheimer’s disease (SavaDx), which they say on their website it has detected >10-fold differences between patients with Alzheimer’s and age-matched normal controls or young cognitively intact subjects. This clinical-stage program is funded by NIH as well.
Their lead neuroscientist, Lindsay H. Burns, PhD, will give a keynote presentation at the Biomarkers for Alzheimer’s Disease Summit, a virtual conference, on July 15, 2020. Dr. Burns’ talk will focus on SavaDx, the Company’s investigational diagnostic to detect Alzheimer’s disease with a simple blood test. https://finance.yahoo.com/news/cassava-sciences-keynote-presentation-savadx-200110208.html
The last time they gave a positive presentation, their stock shot up over 200% in a week https://www.nasdaq.com/articles/cassava-sciences-sava-is-up-200-in-6-days-whats-the-buzz-2019-12-30
From 3/26: Cassava Sciences is continuing the development of proprietary antibodies and other detection systems for use with SavaDx. Assuming technical success with on-going efforts, the Company expects to initiate a validation/disease specificity study with SavaDx in the second half of 2020. Cassava Sciences expects to present a technical update for SavaDx at a major scientific conference in 2020 (July 17)
Looks like majority of the “heavy” owners are not looking to sell until $10+ good deal team! $SAVA
Products and Earnings come onnnn $SAVA
Sitting on 27 AUG 21 $5 calls
$GOSS $INWK $SAVA $MTP
$TALO $NE $OAS $BTE $LLEXQ
HERE ARE SOME SECURITIES THAT ARE BEING HEAVILY LOADED, BY INSTITUTIONAL INVESTORS. AND, IF YOU BUY, YOU SHOULD SEE VERY NICE RETURNS:
$GOSS $INWK $SAVA $MTP
$TALO $NE $OAS $BTE $LLEXQ
NOTE ON LLEXQ:
FILED FOR BANKRUPTCY PROTECTION, BUT, IS UNDER CONTROL OF MAJOR SHAREHOLDER VARDES. VARDES IS SAID TO BE PUSHING FOR CANCELLATION OF SHARES. BUT, DOING SO WOULD CANCEL THEIR MAJORITY POSITION. SO, THAT RUMOR HAS NO MERIT. VARDES IS SAID TO BE BUYING UP ALL OF THE COMMON SHARES, ON THE OTC - THAT IS LIKELY NOT RUMOR. BUY NOW, AND, AS COMMON SHARES DRY UP, THE PRICE WILL GO MUCH HIGHER.